🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with figures suggesting more than 82 million infections each year. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This approval represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Outcomes and Worldwide Availability

As per data released by a major medical journal, the new drug cured more than 90% of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which combines two antibiotics. The research involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Medical professionals treating patients have shared positive views. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea worldwide.